Alcon's Neurotech Acquisition Offers Significant Growth Potential, Needham Says — Oct 21, 2026

Alcon's (ALC) acquisition of Neurotech Pharmaceuticals could become a significant revenue growth…...

Algoma Central Corporation Announces Increase to Previously Announced Bought Deal Offering of 6.20% Convertible Unsecured Subordinated Debentures — Oct 21, 2026

Algoma Central Corporation NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ST. CATHARINES, Ontario, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Algoma Central Corporation ("Algoma") (TSX:ALC) announced today that, due to strong demand, it has entered into a ...

Alcon acquires Neurotech Pharmaceuticals — Oct 20, 2026

* Alcon has acquired privately held Neurotech Pharmaceuticals, providing it ownership of Encelto (revakinagene taroretcel). * The Swiss eye care company paid [https://seekingalpha.com/pr/20693564-alcon-acquires-neurotech-and-encelto-the-only-fda-approved-treatment-for-mactel-type-2] $550M ...

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2 — Oct 20, 2026

Expands Alcon's retina portfolio with ENCELTO, an encapsulated cell therapy intended for surgical implantation in the eye for patients with MacTel Type 2, a rare retinal disease Alcon's established presence and expertise in surgical retina is expected to accelerate commercialization and pa...